Welcome to the BioLogicTube

NovVac 2011

Wed, 31 Aug 2011 15:52:26 GMT

BioLogicMedia Showreel Summer 2011

Mon, 29 Aug 2011 15:50:38 GMT

BioLogicMedia

We are making award-winning audio visual productions for Life science companies, institutions and organisations. From script to screen.

We Translate complex medical information into video productions that are
entertaining, informative, scientifically truthful and visually compelling.

With medical expertise, creative individuals and complete in-house
high-end film production, the company
can participate in all stages from the
birth of concepts and ideas to the execution and delivery of end-stage products.

1. LEARN is an interactive exhibition that takes the shape of an artistically made gigantic vein. It is a “hear-see-feel exhibition”, i.e. is focused on experienced-based learning. The exhibition communicates the esoteric nature of immune mediated inflammatory diseases; Autoimmune diseases that vary in their clinical manifestations, but share common underlying disease mechanisms Visitors can walk around inside the giant vein and see what goes on “when your body becomes your enemy”. The aim of LEARN is to address the stigmas, misperceptions, by increasing the awareness and knowledge of autoimmune diseases. The exhibition had World premiere on June 10th, 2009 in Copenhagen, Denmark, and is currently touring the globe.

2. Doctor Doctor - What is going on? A Hit on BBC.Jesper Eugen-Olsen and Bjørn Vidø worked with patient societies in Denmark to produce the catchy pop video. The Video has its own site on BBC. Check it and sing along.

3. Conference coverage and edutainment. BioLogic Media also offers to cover conference events as well as conference edutainment. An example of edutainment was the Nordic Meeting of Gastroenterology in Copenhagen 8-11 June 2009. In this case the aim was to boost a simple 45 minute dinner lecture on inflammation into an edutainment event. In just 3 days. The solution was to combine a classical power point presentation with live video, live music, light design, smoke machines and sound effects. BioLogic Media provided a thrilling presentation on inflammation to the conference-participating doctors.

4. Dissemination of research results. In most cases, medical research results in scientific publications that only reach peer researchers. At BioLogic Media, we bring the results of research to the general public. An example of this is an EU FP6 funded clinical trial carried out in Guinea-Bissau, West Africa. The study found that a simple blood test (The suPARnostic® assay, ViroGates, Denmark) can predict post-hospital mortality.

novo seeds video - short version

Mon, 29 Aug 2011 12:03:26 GMT

Novo Seeds
Novo Seeds is a life science supporting program launched by the Novo Nordisk Foundation and Novo A/S. Novo Seeds has two components, a pre-seed funding capacity and a seed financing fund. Both aim at identifying and developing the unexplored commercial potential present in academic and early stage applied research projects at universities and biotech companies within life science in Scandinavia.
The pre-seed program supports early stage projects based on ideas and results with commercial potential. Funding is given as grants in the same manner as other grants awarded by the Novo Nordisk Foundation.
The seed fund aims at supporting more advanced projects and will operate on commercial terms, i.e. support is given to projects and companies in exchange for ownership or other rights to the companies/projects. Typically, the seed program will invest in newly formed companies that are too early in their development stage to be supported by Novo A/S’ venture capital or other international investors.
About Novo Seeds
Novo Seeds was launched in September 2007 as a new initiative from Novo A/S and the Novo Nordisk Foundation to provide funding for early stage projects and seed financing of new life science companies in Scandinavia. Through the Novo Seeds programs, the Novo Group can support all stages of life science development, from basic research grants from the Novo Nordisk Foundation through seed funding to venture financing from Novo A/S.
Novo Seeds is based within the Novo A/S organization, and has a large network within the Scandinavian and international biotech industry. We strive to leverage this extensive network to the benefit of our portfolio companies and the projects we support through our pre-seed grants.

Novo Seeds' focus
The pre-seed program is aimed at providing support for commercially interesting projects, typically originating from academic research institutions in Scandinavia, which are too early for seed investments. The pre-seed grants can be used for additional proof-of-principle studies, supportive investigations, and freedom to operate analysis or other activities which are required to prepare the project for a seed financing round.
The seed program focuses on Scandinavian life science companies. Our primary focus is projects for diagnosis, control, treatment, and prevention of disease. Novo Seeds aims to play a leading role in the financing, but welcomes syndication with other investors in its portfolio companies. In addition to financial support, Novo Seeds provides organisational, strategic and other assistance, typically anchored in one or more board seats in the portfolio companies.

http://www.novo.dk/composite-364.htm

NovVac 2011

Mon, 29 Aug 2011 11:34:46 GMT

NovVac is a danish biotech company that has developed an algorithm for identification of antigens that can be used for vaccine development

novo seeds - trailer

Mon, 29 Aug 2011 11:20:18 GMT

Novo Seeds is a life science supporting program launched by the Novo Nordisk Foundation and Novo A/S. Novo Seeds has two components, a pre-seed funding capacity and a seed financing fund. Both aim at identifying and developing the unexplored commercial potential present in academic and early stage applied research projects at universities and biotech companies within life science in Scandinavia.
The pre-seed program supports early stage projects based on ideas and results with commercial potential. Funding is given as grants in the same manner as other grants awarded by the Novo Nordisk Foundation.
The seed fund aims at supporting more advanced projects and will operate on commercial terms, i.e. support is given to projects and companies in exchange for ownership or other rights to the companies/projects. Typically, the seed program will invest in newly formed companies that are too early in their development stage to be supported by Novo A/S’ venture capital or other international investors.
About Novo Seeds
Novo Seeds was launched in September 2007 as a new initiative from Novo A/S and the Novo Nordisk Foundation to provide funding for early stage projects and seed financing of new life science companies in Scandinavia. Through the Novo Seeds programs, the Novo Group can support all stages of life science development, from basic research grants from the Novo Nordisk Foundation through seed funding to venture financing from Novo A/S.
Novo Seeds is based within the Novo A/S organization, and has a large network within the Scandinavian and international biotech industry. We strive to leverage this extensive network to the benefit of our portfolio companies and the projects we support through our pre-seed grants.